ABBVAnother bite at the lymphoma apple
AbbVie and Genmab are back with more good news for their dual-acting cancer drug, epcoritamab. This time, the spotlight is on a frontline lymphoma trial, where the combo turned in a positive result and kept the company’s oncology story looking alive and kicking.
Why investors care
For AbbVie, this is the kind of update that makes the pipeline feel less like a science fair project and more like an actual growth engine. The company still leans heavily on its big established drugs, so every credible cancer win matters — especially when it comes from a drug that could expand into a much bigger patient pool.
The fine print that matters
A few things to keep in mind:
- The headline says the drug scored, but the article content here does not spell out the exact endpoint or numbers.
- That means investors should treat this as a positive readout, not a blank check.
- Still, in biotech-land, a good frontline lymphoma signal can be enough to keep momentum going and the market’s attention glued to the next data drop.
Big picture: AbbVie is trying to prove its future can be built on more than its old hits, and epcoritamab keeps giving that story a little more credibility.